<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>255309</rcn>
  <id>101088596</id>
  <acronym>artFibro</acronym>
  <teaser>Lung cancer is the leading cause of cancer death. Immunotherapy improved survival rates, but efficacy is limited to selected patients. We recently discovered universal antigen presenting fibroblasts (apFibros) across human and murine lung tumors and showed that they directly...</teaser>
  <objective>Lung cancer is the leading cause of cancer death. Immunotherapy improved survival rates, but efficacy is limited to selected patients. We recently discovered universal antigen presenting fibroblasts (apFibros) across human and murine lung tumors and showed that they directly stimulate cancer-specific CD4 T cells, creating immunological hot spots that support immune rejection. These studies achieved a breakthrough on the role of in situ cancer antigen presentation and proposed a novel model whereby tumors can sustain T cells independently of lymph nodes. 

Preliminary data suggest that lung apFibros help overcome resistance to checkpoint inhibitors. For their immunotherapeutic exploitation of apFibros two bottlenecks must be overcome: low numbers and incomplete understanding of their configurations. We will integrate computational and laboratory experiments and work in parallel in human and mouse models to generate perturbation datasets across single-cell/cell systems, transcriptomics/epigenomics, spatial/temporal levels, and dissect the molecular landscape that regulates fibroblast states. Our ultimate goal is to unravel perturbations that can diverge cancer-associated fibroblasts to antigen presenting states.

The following questions are at the core of our proposal i) how do diverse fibroblast states emerge and evolve? ii) which gene regulatory networks drive specificity of these states? ii) which are the functional modules that are driven by apFibros and how are they mechanistically explained?  iv) how can we transdifferentiate existing fibroblasts to acquire antigen presenting states? v) how can fibroblast reprogramming help overcome immunotherapy resistance?

The proposed research should help advance mechanistic concepts in what we term the “adaptive immune mesenchyme”, decode the complexity of peripheral antigen presentation in tumors and beyond and promote targeting of the stroma for immunotherapy.</objective>
  <title>Artifying fibroblasts: Perturbation modelling in the lung tumor phase space to rewire fibroblasts for immunotherapy.</title>
  <totalCost>1997250</totalCost>
  <ecMaxContribution>1997250</ecMaxContribution>
  <startDate>2023-04-01</startDate>
  <endDate>2028-03-31</endDate>
  <ecSignatureDate>2023-03-27</ecSignatureDate>
  <duration>60</duration>
  <status>SIGNED</status>
  <keywords>fibroblasts, mesenchyme, cancer antigens, transdifferentiation, cell reprogramming, immunotherapy, in vivo gene editing</keywords>
  <identifiers>
    <grantDoi>10.3030/101088596</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2025-01-03 10:47:16</sourceUpdateDate>
  <contentCreationDate>2023-07-27 16:47:28</contentCreationDate>
  <contentUpdateDate>2023-07-27 16:47:05</contentUpdateDate>
  <lastUpdateDate>2025-09-19 14:48:40</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>456773</rcn>
        <id>456773-reprogramming-fibroblasts-to-boost-cancer-immunotherapy</id>
        <title>Reprogramming fibroblasts to boost cancer immunotherapy</title>
        <contentUpdateDate>2025-05-15 15:30:29</contentUpdateDate>
        <relations>
          <categories>
            <category classification="applicationDomain" type="isApplicableIn">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/health</code>
              <title>Health</title>
              <displayCode>/Health</displayCode>
            </category>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55605</rcn>
        <title>ERC-2022-COG</title>
        <identifier>ERC-2022-COG</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55605</rcn>
        <title>ERC-2022-COG</title>
        <identifier>ERC-2022-COG</identifier>
      </call>
      <organization netEcContribution="1997250" totalCost="1997250" source="corda" order="1" ecContribution="1997250" terminated="false" sme="false" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1906304</rcn>
        <id>999458610</id>
        <vatNumber>EL090052367</vatNumber>
        <legalName>EREVNITIKO KENTRO VIOIATRIKON EPISTIMON ALEXANDROS FLEMINGK</legalName>
        <shortName>BIOMEDICALSCIENCES RESEARCH CENTER ALEXANDER FLEMING</shortName>
        <address>
          <street>FLEMING STREET 34</street>
          <city>VARI-ATHENS</city>
          <postalCode>16 672</postalCode>
          <country>EL</country>
          <postBox>N/A</postBox>
          <url>http://www.fleming.gr</url>
          <geolocation>37.9226935,23.750136050000002</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/REC</code>
              <title>Research Organisations</title>
              <displayCode>/Research Organisations</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Ανατολική Αττική</name>
              <rcn>1465349</rcn>
              <nutsCode>EL305</nutsCode>
              <parents>
                <region>
                  <name>Aττική</name>
                  <rcn>1464908</rcn>
                  <nutsCode>EL30</nutsCode>
                  <parents>
                    <region>
                      <name>Αττική</name>
                      <rcn>1464907</rcn>
                      <nutsCode>EL3</nutsCode>
                      <parents>
                        <region>
                          <name>Greece</name>
                          <rcn>240552488</rcn>
                          <nutsCode>EL</nutsCode>
                          <euCode>EL</euCode>
                          <isoCode>EL</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Greece</name>
              <rcn>240552488</rcn>
              <nutsCode>EL</nutsCode>
              <euCode>EL</euCode>
              <isoCode>EL</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>706731</rcn>
        <id>HORIZON_ERC-2022-COG</id>
        <code>ERC-2022-COG</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC CONSOLIDATOR GRANTS</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode>/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/155/643</code>
        <title>immunotherapy</title>
        <displayCode>/medical and health sciences/basic medicine/immunology/immunotherapy</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/23/49/337/44114657</code>
        <title>epigenetics</title>
        <displayCode>/natural sciences/biological sciences/genetics/epigenetics</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-ERC</code>
        <title>HORIZON ERC Grants</title>
        <description>HORIZON ERC Grants</description>
        <displayCode>/HORIZON ERC Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>